Novo Nordisk
-
Aspen Pharmacare and Novo Nordisk pioneer local insulin production in Africa to tackle diabetes crisis
SOUTH AFRICA — Africa’s leading pharmaceutical company, Aspen Pharmacare, has entered into a groundbreaking agreement with Danish healthcare firm Novo Nordisk to establish South Africa’s…
-
New York’s attorney general strikes historic deal to cap insulin prices with Novo Nordisk, easing burden on uninsured
USA — In a monumental move, New York Attorney General Letitia James has reached a landmark agreement with Novo Nordisk Inc., one of the nation’s…
-
Wegovy weight-loss injections launch in the UK amid soaring demand and high hopes
UNITED KINGDOM —Novo Nordisk has introduced its Wegovy weight-loss injections to the UK market, marking its entry into the second major European market in just…
-
Novo Nordisk dethrones LVMH as Europe’s corporate champion
DENMARK — In a historic shift of power on the European corporate stage, Danish pharmaceutical giant Novo Nordisk has knocked luxury conglomerate LVMH off its…
-
Novo’s Wegovy proves beneficial for individuals with obesity and heart failure
DENMARK — Novo Nordisk, the Danish pharmaceutical giant, has once again seized the spotlight with groundbreaking revelations about its weight loss drug, Wegovy. Following its…
-
Novo Nordisk teams up with Thermo Fisher to bolster Wegovy supply
DENMARK — In an effort to meet the escalating demand for its sought-after weight-loss drug, Wegovy, Novo Nordisk has enlisted Thermo Fisher as a contract…
-
Novo Nordisk’s aggressive lobbying aims to revolutionize obesity drug coverage
USA — In a bold bid to reshape the landscape of Medicare coverage, Novo Nordisk, the pharmaceutical force behind weight loss therapies Ozempic and Wegovy,…
-
Viatris forges ahead with Ozempic and Wegovy generics amid legal tussle with Novo Nordisk
USA — Viatris Pharmaceuticals is currently awaiting regulatory verdicts on its generic versions of the widely used type 2 diabetes drug Ozempic and the breakthrough…
-
Novo Nordisk ramps up projections for obesity and diabetes drugs amidst cardiovascular breakthrough
DENMARK — Novo Nordisk, a pioneering force in diabetes and obesity treatments, is boldly elevating its forecasts following groundbreaking results showcasing the cardiovascular benefits of…
-
Wegovy’s heart benefits shine in Novo Nordisk trial, reducing risk of problems
DENMARK —Novo Nordisk has released groundbreaking data from a major trial that showcases Wegovy’s remarkable ability to reduce the risk of “adverse cardiovascular events” by…